^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    6-gene signature

    over1year
    🔥Biomarker analysis from phs-II study of nivolumab in biliary tract cancer🔥 https://t.co/9hkI3ENDCY 👉potential candidates: tumor PD-L1, CD8 T cell infiltration and high ratio of CD8/reg. T cells, 6-gene signature ❗️promising, but we need more @myESMO @OncoAlert @enscca (@ArndtVogel)
    IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
    |
    6-gene signature
    |
    Opdivo (nivolumab)